Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
J Gynecol Oncol. 2024 May;35(3):e39. doi: 10.3802/jgo.2024.35.e39. Epub 2023 Dec 20.
To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT).
A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study.
The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years. According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210 (65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1-276 months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%) patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914-19.878; p=0.002), 3.755-fold in stage II-IV (95% CI=1.275-11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017-6.233; p=0.046) increased.
In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.
定义成人颗粒细胞瘤(AGCT)患者的临床、组织病理学特征和影响生存的预后因素。
本研究纳入了 1988 年至 2021 年期间在 9 个三级肿瘤中心接受治疗的最终病理结果为 AGCT 的 322 例患者。
患者的平均年龄为 51.3±11.8 岁,年龄范围为 21 至 82 岁。根据 2014 年国际妇产科联合会的分期标准,250 例(77.6%)患者为Ⅰ期,24 例(7.5%)患者为Ⅱ期,20 例(6.2%)患者为Ⅲ期,3 例(7.8%)患者为Ⅳ期。210 例(65.2%)患者在手术过程中进行了淋巴结切除术。7 例(3.3%)患者存在淋巴结受累。19 例(5.9%)患者腹膜细胞学检查阳性,13 例(4%)患者大网膜转移。在 285 例行子宫切除术的患者中,19 例(6.7%)患者有复杂增生伴不典型/子宫内膜上皮内瘤变,8 例(2.8%)患者有Ⅰ级子宫内膜样腺癌。研究组中发现 93 例(28.9%)患者接受了辅助治疗。博来霉素、依托泊苷、顺铂是最常用的化疗方案。研究组的中位随访时间为 41 个月(范围 1-276 个月)。在此期间,34 例(10.6%)患者复发,9 例(2.8%)患者因疾病死亡。整个队列的 5 年无病生存率(DFS)为 86%,5 年疾病特异性生存率为 98%。仅 13 例患者盆腔内和 7 例患者腹腔外出现复发。腹膜细胞学检查阳性患者的复发率增加 6.168 倍(95%置信区间[CI]=1.914-19.878;p=0.002),Ⅱ-Ⅳ期患者增加 3.755 倍(95%CI=1.275-11.063;p=0.016),绝经后妇女增加 2.517 倍(95%CI=1.017-6.233;p=0.046)。
在这项研究中,AGCT 患者中有 3.3%的患者存在淋巴结受累。因此,我们得出结论,在原发性手术治疗中可以避免淋巴结切除术。阳性腹膜细胞学检查、分期和绝经状态是 DFS 的独立预后预测因素。